Blocking IL-17a Signaling Decreases Lung Inflammation and Improves Alveolarization in Experimental Bronchopulmonary Dysplasia
The American Journal of Pathology · 2024
DOI: 10.1016/j.ajpath.2024.07.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Pathology, 2024. Verfasst von Meagan Goates und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neonatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Interleukin-17, Signal Transduction, Lipopolysaccharides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NICHD NIH HHS, Baylor College of Medicine.
Abstract (Originalsprache)
Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of preterm infants that is associated with life-long morbidities. Inflammatory insults contribute to BPD pathogenesis. Although the proinflammatory cytokine, IL-17a, plays a role in various neonatal inflammatory disorders, its role in BPD pathogenesis is unclear. To test the hypothesis that blocking IL-17a signaling decreases lipopolysaccharide (LPS)-mediated experimental BPD in neonatal mice, wild-type mice were injected intraperitoneally with phosphate-buffered saline or LPS during the saccular lung developmental phase. Pulmonary IL-17a expression was determined by enzyme-linked immunosorbent assay and by flow cytometry. LPS-injected mice had higher pulmonary IL-17a protein levels and IL-17a+ and IL-22+ cells. γδ T cells, followed by non-T lymphoid cells, were the primary producers of IL-17a. Wild-type mice were then injected intraperitoneally with isotype antibody (Ab) or IL-17a Ab, while they were treated with phosphate-buffered saline or LPS, followed by quantification of lung inflammatory markers, alveolarization, vascularization, cell proliferation, and apoptosis. LPS-mediated alveolar simplification, apoptosis, and cell proliferation inhibition were significantly greater in mice treated with isotype Ab than in those treated with IL-17a Ab. Furthermore, STAT1 activation and IL-6 levels were significantly greater in LPS-exposed mice treated with isotype Ab than in those treated with IL-17a Ab. The study results indicate that blocking IL-17a signaling decreases LPS-mediated experimental BPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Neonatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
- Department of Microbiology and Immunology, University of Utah, Salt Lake City, Utah.
- Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas.
- Division of Neonatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. Electronic address: shivanna@bcm.edu.
Förderung
- NHLBI NIH HHS
- NICHD NIH HHS
- Baylor College of Medicine
- National Institutes of Health
- American Academy of Pediatrics
Zitieren
APA
Goates, M., Shrestha, A., Thapa, S., Bettini, M., Barrios, R., & Shivanna, B. (2024). Blocking IL-17a Signaling Decreases Lung Inflammation and Improves Alveolarization in Experimental Bronchopulmonary Dysplasia. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2024.07.011
Vancouver
Goates M, Shrestha A, Thapa S, Bettini M, Barrios R, Shivanna B. Blocking IL-17a Signaling Decreases Lung Inflammation and Improves Alveolarization in Experimental Bronchopulmonary Dysplasia. The American Journal of Pathology. 2024. doi:10.1016/j.ajpath.2024.07.011
BibTeX
@article{Goates2024,
author = {Goates, Meagan and Shrestha, Amrit and Thapa, Shyam and Bettini, Matthew and Barrios, Roberto and Shivanna, Binoy},
title = {Blocking IL-17a Signaling Decreases Lung Inflammation and Improves Alveolarization in Experimental Bronchopulmonary Dysplasia},
journal = {The American Journal of Pathology},
year = {2024},
doi = {10.1016/j.ajpath.2024.07.011}
}
EUVIMED